Two Phase 1b Studies Evaluating the Safety and Tolerability of BET Inhibitors, ABBV-744 and Mivebresib, as Monotherapies and in Combination with Ruxolitinib or Navitoclax in Patients with Myelofibrosis

被引：5
|
作者：
Mascarenhas, John
Saab, Rabih
Brackman, Deanna
Modi, Dimple A.
Abraham, Linu
Ward, James E.
Verstovsek, Srdan
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-137686
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 46 条
  • [1] Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study
    Gupta, Vikas
    Wolleschak, Denise
    Hasselbalch, Hans
    Vannucchi, Alessandro Maria
    Koschmieder, Steffen
    Cervantes, Francisco
    Li, Yang
    Dong, Tuochuan
    Wroclawska, Monika
    Bharathy, Savita
    Harrison, Claire
    BLOOD ADVANCES, 2020, 4 (13) : 3063 - 3071
  • [2] Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis
    Gupta, Vikas
    Harrison, Claire N.
    Hasselbalch, Hans
    Pieri, Lisa
    Koschmieder, Steffen
    Cervantes, Francisco
    Bao, Weichao
    Kalambakas, Stacey
    Atienza, Edric
    Gopalakrishna, Prashanth
    Heidel, Florian H.
    BLOOD, 2015, 126 (23)
  • [3] Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis
    Couban, Stephen
    Benevolo, Giulia
    Donnellan, William
    Cultrera, Jennifer
    Koschmieder, Steffen
    Verstovsek, Srdan
    Hooper, Gregory
    Hertig, Christian
    Tandon, Maneesh
    Dimier, Natalie
    Templeton, Ian
    Passamonti, Francesco
    BLOOD, 2017, 130
  • [4] A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study Evaluating Navitoclax in Combination with Ruxolitinib in Patients with Myelofibrosis (TRANSFORM-1)
    Potluri, Jalaja
    Harb, Jason
    Masud, Abdullah A.
    Hutti, Jessica E.
    BLOOD, 2020, 136
  • [5] Design for a Phase 1b study evaluating the safety and tolerability of a 4-week continuous subcutaneous infusion of ABBV-951 in Parkinson's disease patients
    Facheris, M.
    Locke, C.
    Qi, X.
    Robieson, W.
    Rosebraugh, M.
    Benesh, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 466 - 466
  • [6] Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis
    Gupta, Vikas
    Koschmieder, Steffen
    Harrison, Claire N.
    Cervantes, Francisco
    Heidel, Florian H.
    Drummond, Mark
    Rey, Jerome
    Hurh, Eunju
    Bao, Weichao
    Rampersad, Anita
    Kalambakas, Stacey
    Vannucchi, Alessandro Maria
    BLOOD, 2014, 124 (21)
  • [7] A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
    Weekes, Colin
    Lockhart, A. Craig
    Lee, James J.
    Sturm, Isrid
    Cleton, Adriaan
    Huang, Funan
    Lenz, Heinz-Josef
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (09) : 2450 - 2458
  • [8] Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis
    Durrant, Simon T.
    Nagler, Arnon
    Guglielmelli, Paola
    Lavie, David
    le Coutre, Philipp
    Gisslinger, Heinz
    Chuah, Charles
    Maffioli, Margherita
    Bharathy, Savita
    Dong, Tuochuan
    Wroclawska, Monika
    Martinez Lopez, Joaquin
    HAEMATOLOGICA, 2019, 104 (12) : E551 - E554
  • [9] Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors
    Stradella, Agostina
    Johnson, Melissa
    Goel, Sanjay
    Park, Haeseong
    Lakhani, Nehal
    Arkenau, Hendrik-Tobias
    Galsky, Matthew D.
    Calvo, Emiliano
    Baz, Vicente
    Moreno, Victor
    Saavedra, Omar
    Luen, Stephen J.
    Mu, Song
    Wan, Qiting
    Chang, Victoria
    Zhang, Wa
    Barve, Minal
    CANCER MEDICINE, 2024, 13 (13):
  • [10] A phase 1b study evaluating the safety and pharmacokinetics (PK) of regorafenib (REG) in combination with cetuximab (CTX) in patients with advanced solid tumors
    Weekes, C.
    Lockhart, A. C.
    Lenz, H-J.
    Lee, J. J.
    Cleton, A.
    Huang, F.
    Sturm, I.
    ANNALS OF ONCOLOGY, 2017, 28
12345